RecruitingPHASE1, PHASE2NCT04588922
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Studying Chronic myeloid leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sellas Life Sciences Group
- Principal Investigator
- Dragan Cicic, MDSELLAS Life Sciences Group, Inc.
- Intervention
- SLS009(drug)
- Enrollment
- 160 target
- Eligibility
- 12 years · All sexes
- Timeline
- 2021 – 2027
Study locations (25)
- O'Neal Comprehensive Cancer Center, University of Alabama, Birmingham, Alabama, United States
- City of Hope - Phoenix, Goodyear, Arizona, United States
- City of Hope National Medical Center, Duarte, California, United States
- City of Hope - Atlanta, Newnan, Georgia, United States
- City of Hope - Chicago, Zion, Illinois, United States
- Ochsner Clinic Foundation, New Orleans, Louisiana, United States
- Clinical Research Alliance, Inc., Lake Success, New York, United States
- New York - Presbyterian Hospital, New York, New York, United States
- UNC School of Medicine, Division of Hematology, Chapel Hill, North Carolina, United States
- Bon Secours St. Francis Cancer Center, Greenville, South Carolina, United States
- Baylor Scott & White Health, Dallas, Texas, United States
- MD Anderson, Houston, Texas, United States
- The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
- Anhui Provincial Hospital, Hefei, Anhui, China
- Affiliated Cancer Hospital of Chongqing University, Chongqing, Chongqing Municipality, China
- +10 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04588922 on ClinicalTrials.govOther trials for Chronic myeloid leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07354074Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CPNovartis Pharmaceuticals
- RECRUITINGNCT07375355Real-world Study of Scemblix in the Treatment of Chronic Myeloid Leukemia in ChinaNovartis Pharmaceuticals
- ENROLLING BY INVITATIONNCT07383298Observational Study on Dose Optimization of Olverembatinib in Patients With Chronic Myeloid Leukemia in Chronic or Accelerated PhaseQian Jiang
- RECRUITINGPHASE2NCT06817720Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic PhaseM.D. Anderson Cancer Center
- RECRUITINGNCT07061145A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid LeukemiaAzienda USL Reggio Emilia - IRCCS
- RECRUITINGPHASE2NCT06409936PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CMLGruppo Italiano Malattie EMatologiche dell'Adulto
- RECRUITINGPHASE2NCT06514534Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.Novartis Pharmaceuticals
- RECRUITINGPHASE1NCT06787144ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese ParticipantsEnliven Therapeutics